Role of NS5A-L31/Y93 Double Wild-type in Failure of Glecaprevir/Pibrentasvir Double Therapy in Two Patients with a History of Direct-acting Antiviral Agent Failure: An Ultra-deep Sequencing Analysis-Reference-Cited by-同舟云学术

Role of NS5A-L31/Y93 Double Wild-type in Failure of Glecaprevir/Pibrentasvir Double Therapy in Two Patients with a History of Direct-acting Antiviral Agent Failure: An Ultra-deep Sequencing Analysis

Published:2019-09-15 Issue:18 Volume:58 Page:2657-2662
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Sano Tomoya¹,Akuta Norio¹,Suzuki Fumitaka¹,Kasuya Kayoko¹,Fujiyama Shunichiro¹,Kawamura Yusuke¹,Sezaki Hitomi¹,Hosaka Tetsuya¹,Saitoh Satoshi¹,Kobayashi Masahiro¹,Suzuki Yoshiyuki¹,Kobayashi Mariko²,Arase Yasuji¹,Ikeda Kenji¹,Kumada Hiromitsu¹

Affiliation:

1. Department of Hepatology, Toranomon Hospital, Japan

2. Liver Research Laboratory, Toranomon Hospital, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/58/18/58_2604-18/_pdf

Reference13 articles.

1. 1. Ng TI, Krishnan P, Pilot-Matias T, et al. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir. Antimicrob Agents Chemother 61: e02558, 2017.

2. 2. Ng T, Tripathi R, Dekyhyar T, et al. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3-4A protease inhibitor glecaprevir. Antimicrob Agents Chemother 62: e01620, 2017.